/ 2 items

#ELVN↓

Enliven Therapeutics Announces Promising Results for CML Treatment

ELVN/ 01/08/2026 · 9:58 AM

ELVN-001 Shows 69% Response Rate in CML Phase 1b Trial Results

Enliven Therapeutics (ELVN) reports encouraging Phase 1b results for ELVN-001, a new treatment for chronic myeloid leukemia, with strong response rates and excellent safety profile.

TERN/ 11/03/2025 · 11:00 AM

William Blair Upgrades Terns Pharmaceuticals to Outperform After Strong TERN-701 Data

William Blair upgraded Terns Pharmaceuticals (TERN) to Outperform following impressive Phase 1 CARDINAL trial results of TERN-701 in chronic myeloid leukemia, showing a 75% overall major molecular response rate and strong safety profile.